Lynovex

Lynovex® (NM001) is a first-in-class orphan drug candidate for cystic fibrosis.

NovaBiotics recognises that new, effective treatments are desperately needed to address these symptoms.

Our solution is Lynovex® (NM001), which is being developed to improve the quality & length of life of all CF patients – not just those with particular CFTR genotypes.

See the effect of Lynovex on cystic fibrosis sputum

What Is Lynovex?
The Story So Far
Clinical Studies
Lynovex® Latest

Lynovex® Latest

Care Cf 1 Oral Lynovex Clinical Trial Data Published

Patients at the centre of rare disease therapy development

Three Posters on New Lynovex Preclinical and Clinical Data

Novabiotics To Present New Data On Their Novel Cystic Fibrosis Drugs At The European Cf Society’S Annual Conference

Novabiotics Presenting New Data At European Cystic Fibrosis Conference